CTLA4 and neoplasm: In various tumor types, increased expression of the T‐cell costimulatory molecule (ICOS) on PBLs and TILs has been observed after CTLA4 blockade, suggesting that ICOS on immune cells may serve as a potential biomarker for anti‐CTLA‐4 therapy.103